Oculis Holding AG Ordinary shares (NYSE: OCS) — Healthcare · Share Price, Chart & Market Data
About: Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $26.44 (-1.23%)
OCSOculis Holding AG Ordinary shares
Loading watchlist status…
Trade OCS now
Oculis Holding AG Ordinary shares share price
OCS price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 11:05 am GMT+0
OCS price performance
-3.433%
5D
7.088%
1M
32.2%
YTD
48.04%
1Y
OCS price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NYSE rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 11:05 am GMT+0
OCS details
OCS Market Signals